Jeffrey S. Chamberlain mostly deals with Duchenne muscular dystrophy, Dystrophin, Muscular dystrophy, Molecular biology and Cell biology. His Duchenne muscular dystrophy research integrates issues from Viral vector, Genetic enhancement and Pathology. His Dystrophin research is multidisciplinary, incorporating perspectives in Sarcolemma and Exon.
His Muscular dystrophy research includes elements of Transgene, Bioinformatics, Anatomy, Skeletal muscle and Side population. His study in Anatomy is interdisciplinary in nature, drawing from both Endocrinology and Internal medicine, Isometric exercise. His Molecular biology research incorporates elements of Cardiac muscle, Regulation of gene expression, Gene, Myocyte and Myosin.
Jeffrey S. Chamberlain mainly investigates Dystrophin, Duchenne muscular dystrophy, Muscular dystrophy, Cell biology and Molecular biology. Jeffrey S. Chamberlain mostly deals with Utrophin in his studies of Dystrophin. His work carried out in the field of Duchenne muscular dystrophy brings together such families of science as Genetic enhancement, Bioinformatics and Skeletal muscle.
His Genetic enhancement research incorporates themes from Vector, Viral vector, Transgene and Virology. His studies deal with areas such as Dystrophy, Pathology, Immunology and Gene delivery as well as Muscular dystrophy. His Molecular biology research includes themes of Gene expression, Transfection, Complementary DNA, Exon and Adenoviridae.
His primary areas of study are Duchenne muscular dystrophy, Dystrophin, Genetic enhancement, Cell biology and Bioinformatics. His research integrates issues of Adeno-associated virus, Cardiomyopathy, Anatomy, Skeletal muscle and Muscular dystrophy in his study of Duchenne muscular dystrophy. His Muscular dystrophy study combines topics in areas such as Degenerative disease and Pathology.
Jeffrey S. Chamberlain has researched Dystrophin in several fields, including Sarcolemma, Vector and Genome editing. His Genetic enhancement study incorporates themes from Internal medicine, Clinical trial, Viral vector and Virology. His study in the field of Function, Progenitor cell and Myocyte is also linked to topics like Nebulin.
The scientist’s investigation covers issues in Dystrophin, Duchenne muscular dystrophy, Genetic enhancement, Muscular dystrophy and Cell biology. The Dystrophin study combines topics in areas such as Exon skipping, Actin cytoskeleton, Spectrin and Gene isoform. His studies in Duchenne muscular dystrophy integrate themes in fields like Adeno-associated virus and CRISPR.
His Genetic enhancement research is multidisciplinary, relying on both Histology, Pathology, Viral vector and Bioinformatics. The various areas that he examines in his Muscular dystrophy study include Ex vivo, Binding site, Muscle contraction and Creatine kinase. His work deals with themes such as Vector, In vivo and Skeletal muscle, which intersect with Cell biology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification
Jeffrey S. Chamberlain;Richard A. Gibbs;Joel E. Rainer;Phi Nga Nguyen;Phi Nga Nguyen.
Nucleic Acids Research (1988)
Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells.
Arianna Dellavalle;Maurilio Sampaolesi;Rossana Tonlorenzi;Enrico Tagliafico.
Nature Cell Biology (2007)
Systemic delivery of genes to striated muscles using adeno-associated viral vectors.
Paul Gregorevic;Michael J Blankinship;James M Allen;Robert W Crawford.
Nature Medicine (2004)
Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy
Scott Q. Harper;Michael A. Hauser;Michael A. Hauser;Christiana DelloRusso;Christiana DelloRusso;Dongsheng Duan.
Nature Medicine (2002)
X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus.
J. A. Towbin;J. F. Hejtmancik;P. Brink;B. Gelb.
Circulation (1993)
Animal models for muscular dystrophy show different patterns of sarcolemmal disruption
Volker Straub;Jill A. Rafael;Jeffrey S. Chamberlain;Kevin P. Campbell.
Journal of Cell Biology (1997)
Identification and Characterization of the Dystrophin Anchoring Site on β-Dystroglycan
Daniel Jung;Bin Yang;Bin Yang;Jon Meyer;Jon Meyer;Jeffrey S. Chamberlain.
Journal of Biological Chemistry (1995)
Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy
Yi Lai;Gail D. Thomas;Yongping Yue;Hsiao T. Yang.
Journal of Clinical Investigation (2009)
Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity
Gregory A. Cox;Neil M. Cole;Kiichiro Matsumura;Stephanie F. Phelps.
Nature (1993)
rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.
Paul Gregorevic;James M Allen;Elina Minami;Michael J Blankinship.
Nature Medicine (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Washington
Baylor College of Medicine
Fred Hutchinson Cancer Research Center
University of Iowa
University of Michigan–Ann Arbor
Fred Hutchinson Cancer Research Center
University of Missouri
Duke University
Boston Children's Hospital
University of Washington
McGill University
PSL University
University of the Ryukyus
Alfaisal University
University of California, Los Angeles
Michigan Technological University
University of Aberdeen
South Australian Water Corporation
University of Amsterdam
German Red Cross
University of Manchester
University of Clermont Auvergne
University of Pennsylvania
Wake Forest University
Hirslanden Private Hospital Group
Deutsches Elektronen-Synchrotron DESY